We develop RNA-based medicines to reprogram immune response in cancer and immune disorders
Finding safer and more effective therapeutic approaches for cancer and autoimmune diseases.
RNA-based therapies against cancer and autoimmune diseases
T-ONE Therapeutics stems from the vision of a group of researchers aiming to exploit innovative RNA-based therapies to fight a wide spectrum of human pathologies, like cancer and autoimmune diseases.
The mission of T-ONE Therapeutics is to develop a novel pharmacological approach to specifically target RNA molecules transcribed from repetitive sequences of the human genome called LINE1 elements. We recently discovered that LINE1-derived RNAs accumulate in the nuclei of T lymphocytes with an impaired immune effector function, such as dysfunctional T cells derived from tumor tissues.
Importantly, we found that pharmacological inhibition of LINE1-derived RNAs through antisense oligonucleotides (ASOs) in TILs (Tumor Infiltrating Lymphocytes) reinvigorates the immune response against tumors. Thus, LINE1 represent a promising therapeutic target to modulate the immune response in several pathological contexts.
Objectives
To develop a novel RNA-based immunotherapy approach to treat cancer and autoimmune diseases through the targeting of LINE1 elements.
LINE1 RNA
LINE1-derived RNAs accumulate in the nuclei of dysfunctional T lymphocytes and impair their immune effector function.
ASO therapies
Antisense oligonucleotides that inhibit LINE1-derived RNAs and reinvigorate the immune response against tumors.
Our discovery in the media
